26-06-2020
ricochet64 / Shutterstock.com
The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
English Court of Appeal, Mylan, Neurim, generic, injunction, insomnia, patent infringement, Circadin
English High Court denies Mylan a stay in Neurim litigation
02-11-2021
Neurim prevails against Mylan in suit over insomnia drug
08-12-2020
Australian court affirms Mylan patent invalidation
06-07-2020
Mylan scores multiple sclerosis patent win over Biogen
23-06-2020
English court gives Mylan green-light to sell generic insomnia drug
04-06-2020
